These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 31764593)

  • 1. Compatibility of [99mTc]Tc-EDDA/HYNIC-TOC and [68Ga] Ga-DOTA-TOC in a syringe for intravenous administration.
    Chaib S; Hallouard F; Chennell P; Darcissac C; Morelec I; Rioufol C; Sautou V; Fraysse M
    Nucl Med Commun; 2020 Jan; 41(1):11-17. PubMed ID: 31764593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stability Study of [18F]Fludeoxyglucose and [18F]Fluorocholine in Different Medical Devices for Intravenous Administration.
    Hallouard F; Sauze W; Emery S; Skanjeti A; Rioufol C; Fraysse M
    Curr Radiopharm; 2018; 11(2):138-146. PubMed ID: 29972107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limitations and pitfalls of 99mTc-EDDA/HYNIC-TOC (Tektrotyd) scintigraphy.
    Garai I; Barna S; Nagy G; Forgacs A
    Nucl Med Rev Cent East Eur; 2016; 19(2):93-8. PubMed ID: 27479887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative analysis of 99mTc-depreotide and 99mTc-EDDA/HYNIC-TOC thorax scintigrams acquired for the purpose of differential diagnosis of solitary pulmonary nodules.
    Płachcińska A; Mikołajczak R; Kozak J; Rzeszutek K; Kuśmierek J
    Nucl Med Rev Cent East Eur; 2006; 9(1):24-9. PubMed ID: 16791800
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Briganti V; Cuccurullo V; Berti V; Di Stasio GD; Linguanti F; Mungai F; Mansi L
    Curr Radiopharm; 2020; 13(3):166-176. PubMed ID: 31886756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of PET/CT 68Ga somatostatin receptor imaging on proceeding with patients, who were previously diagnosed with 99mTc-EDDA/HYNIC-TOC SPECT.
    Madrzak D; Mikołajczak R; Kamiński G
    Nucl Med Rev Cent East Eur; 2016; 19(2):88-92. PubMed ID: 27479886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kit preparation and biokinetics in women of 99mTc-EDDA/HYNIC-E-[c(RGDfK)]2 for breast cancer imaging.
    Ortiz-Arzate Z; Santos-Cuevas CL; Ocampo-García BE; Ferro-Flores G; García-Becerra R; Estrada G; Gómez-Argumosa E; Izquierdo-Sánchez V
    Nucl Med Commun; 2014 Apr; 35(4):423-32. PubMed ID: 24335877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 99mTc-EDDA/HYNIC-TOC in management of patients with head and neck somatostatin receptor positive tumors.
    Trogrlic M; Tezak S
    Nucl Med Rev Cent East Eur; 2016; 19(2):74-80. PubMed ID: 27479884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors.
    Gabriel M; Decristoforo C; Donnemiller E; Ulmer H; Watfah Rychlinski C; Mather SJ; Moncayo R
    J Nucl Med; 2003 May; 44(5):708-16. PubMed ID: 12732671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of neuroendocrine tumors with 99mTc-EDDA/HYNIC TOC.
    Artiko V; Afgan A; Petrović J; Radović B; Petrović N; Vlajković M; Šobić-Šaranović D; Obradović V
    Nucl Med Rev Cent East Eur; 2016; 19(2):99-103. PubMed ID: 27479786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two peptide receptor ligands (99m)Tc-EDDA/HYNIC-Tyr(3)-octreotide and (99m)Tc-EDDA/HYNIC-(D)Glu-octagastrin for scintigraphy of medullary thyroid carcinoma.
    Kosowicz J; Mikołajczak R; Czepczyński R; Ziemnicka K; Gryczyńska M; Sowiński J
    Cancer Biother Radiopharm; 2007 Oct; 22(5):613-28. PubMed ID: 17979564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved kit formulation for preparation of (99m)Tc-HYNIC-TOC: results of preliminary clinical evaluation in imaging patients with neuroendocrine tumors.
    Korde A; Mallia M; Shinto A; Sarma HD; Samuel G; Banerjee S
    Cancer Biother Radiopharm; 2014 Nov; 29(9):387-94. PubMed ID: 25379612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
    Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR
    J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of accumulation of 99mTc-octreotide and 99mTc-EDDA/HYNIC-Tyr3-octreotide in the rat kidneys.
    Kopecky M; Semecky V; Trejtnar F; Laznicek M; Laznickova A; Nachtigal P; Decristoforo C; Mather SJ; Mäcke HR
    Nucl Med Biol; 2004 Feb; 31(2):231-9. PubMed ID: 15013489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 99mTc-EDDA/HYNIC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours; first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives.
    Decristoforo C; Mather SJ; Cholewinski W; Donnemiller E; Riccabona G; Moncayo R
    Eur J Nucl Med; 2000 Sep; 27(9):1318-25. PubMed ID: 11007513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatostatin receptor scintigraphy using 99mTc-EDDA/HYNIC-TOC in patients with medullary thyroid carcinoma.
    Czepczyński R; Parisella MG; Kosowicz J; Mikołajczak R; Ziemnicka K; Gryczyńska M; Sowiński J; Signore A
    Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1635-45. PubMed ID: 17530247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiopharmaceutical development of a freeze-dried kit formulation for the preparation of [99mTc-EDDA-HYNIC-D-Phe1, Tyr3]-octreotide, a somatostatin analog for tumor diagnosis.
    Guggenberg EV; Mikolajczak R; Janota B; Riccabona G; Decristoforo C
    J Pharm Sci; 2004 Oct; 93(10):2497-506. PubMed ID: 15349959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of tricine and EDDA as Co-ligands for 99mTc-labeled HYNIC-MSH analogs for melanoma imaging.
    Garcia MF; Zhang X; Gallazzi F; Fernandez M; Moreno M; Gambini JP; Porcal W; Cabral P; Quinn TP
    Anticancer Agents Med Chem; 2015; 15(1):122-30. PubMed ID: 25175799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A freeze-dried kit formulation for the preparation of Lys(27)(99mTc-EDDA/HYNIC)-Exendin(9-39)/99mTc-EDDA/HYNIC-Tyr3-Octreotide to detect benign and malignant insulinomas.
    Medina-García V; Ocampo-García BE; Ferro-Flores G; Santos-Cuevas CL; Aranda-Lara L; García-Becerra R; Ordaz-Rosado D; Melendez-Alafort L
    Nucl Med Biol; 2015 Dec; 42(12):911-6. PubMed ID: 26364504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 99mTc-EDDA/HYNIC-TOC in the diagnosis of differentiated thyroid carcinoma refractory to radioiodine treatment.
    Czepczyński R; Gryczyńska M; Ruchała M
    Nucl Med Rev Cent East Eur; 2016; 19(2):67-73. PubMed ID: 27479883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.